A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 20 May 2024
At a glance
- Drugs Venetoclax (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors AbbVie
- 29 Mar 2024 Results developing develop a model to describe M-protein dynamics in MM subjects receiving venetoclax and assessing the utility of early M-protein measurements in predicting progression-free survival (PFS) and overall survival (OS), presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 Jan 2024 Results investigating exposure-response relationships of venetoclax published in the Hematological Oncology
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.